Toward replacement of the monkey neurovirulence test in vaccine safety testing

Procedia in Vaccinology

Volumn 5, Issue , 2011, Pages 261-265

  Rubin, Steven A ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

MAPREC; Monkey; MPS; Neurovirulence safety testing; Vaccine

Indexed keywords

MUMPS VACCINE; POLIOMYELITIS VACCINE; VACCINE;

ANIMAL TESTING REPLACEMENT; ARTICLE; ENZYME ANALYSIS; HUMAN; MASSIVELY PARALLEL SEQUENCING; MEDICAL LITERATURE; MONKEY NEUROVIRULENCE TEST; MUTATION; MUTATION ANALYSIS BY PCR AND RESTRICTION ENZYME CLEAVAGE; NEUROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VALIDATION STUDY; VIRAL CONTAMINATION; VIRULENCE; WILD TYPE;

EID: 84555191800     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2011.10.027     Document Type: Article

References (24)

1. Plotkin SL, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA eds. Vaccines. Saunders. 2008: 1-16.
2. European Pharmacopeia Commission. Tests for neurovirulence of live virus vaccines (General method No. 2.6.18). In: Anonymous European Pharmacopeia. 1997: 99.
3. World Health Organization. Requirements for measles, mumps and rubella vaccines and combined vaccine (live). 840, 101-151. 1994. WHO Technical Report Series.
4. World Health Organization. Recommendations for the production and control of poliomyeltis vaccine (oral). 904, 31-93. 2002. WHO Technical Report Series.
5. World Health Organization. Requirements for yellow fever vaccine. 872, 31-68. 1998. WHO Technical Report Series.
6. World Health Organization. Guidelines for the production and quality control of Japanese encephalitis vaccine (live) for human use. 910, 66-98. 2002. WHO Technical Report Series.
7. Levenbook I.S., Pelleu L.J., Elisberg B.L. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J Biol Stand 1987, 15:305-313.
8. Fox J.P., Penna H.A. Behavior of 17D yellow fever virus in rhesus monkeys. Relation to substrain, dose, and neural or extraneural inoculation. Am J Hyg. 1943, 38:152-172.
9. Sabin AB. Properties of attenuated polioviruses and their behavior in human beings. Special Publications of the New York Academy of Sciences 1957;V:113-127.
10. Rubin S.A., Snoy P.J., Wright K.E., Brown E.G., Reeve P., Beeler J.A., Carbone K.M. The mumps virus neurovirulence safety test in Rhesus monkeys: a comparison of mumps virus strains. J Infect Dis 1999, 180:521-525.
11. Afzal M.A., Marsden S., Hull R.M., Pipkin P.A., Bently M.L., Minor P.D. Evaluation of the neurovirulence test for mumps vaccines. Biologicals 1999, 27:43-49.
12. Balraj V., Miller E. Complications of mumps vaccines. Reviews in Medical Virology 1995, 5:219-227.
13. Dragunsky E., Nomura T., Karpinski K., Furesz J., Wood D.J., Pervikov Y., et al. Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study. Bull World Health Organ 2003, 81:251-260.
14. Levenbook I., Dragunsky E., Pervikovc Y. Development of a transgenic mouse neurovirulence test for oral poliovirus vaccine: international collaborative study 1993-1999. Vaccine. 2000, 19:163-166.
15. Rubin S.A., Afzal M.A., Powell C.L., Bentley M.L., Auda G.R., Taffs R.E., Carbone K.M. The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study. J Infect Dis 2005, 191:1123-1128.
16. Qi L., Carbone K., Ye Z., Liu T., Ovanesov K., Pletnikov M., et al. Genetic contributions to influenza virus attenuation in the rat brain. J Neurovirol 2008, 14:136-142.
17. Rubin S., Liu D., Pletnikov M., McCullers J., Ye Z., Levandowski R., et al. Wild-type and attenuated influenza virus infection of the neonatal rat brain. J Neurovirol 2004, 10:305-314.
18. Li Z., Rubin S.A., Taffs R.E., Merchlinsky M., Ye Z., Carbone K.M. Mouse neurotoxicity test for vaccinia-based smallpox vaccines. Vaccine. 2004, 22:1486-1493.
19. Zhang C.X., Sauder C., Malik T., Rubin S.A. A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines. Biologicals 2010, 38:278-283.
20. Monath T.P., Myers G.A., Beck R.A., Knauber M., Scappaticci K., Pullano T., et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 2005, 33:131-144.
21. Evans D.M.A., Dunn G., Minor P.D., Schild G.C., Cann A.J., Stanway G., et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 1985, 314:548-550.
22. Chumakov K.M., Powers L.B., Noonan K.E., Roninson I.B., Levenbook I.S. Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci USA 1991, 88:199-203.
23. Neverov A, Chumakov KM. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. In Press, PNAS 2010.
24. Wood D., Neurovirulence Dev Biol Stand 1999, 101:127-129.